[{"id":"65969d8a-b172-4873-a916-4494ff06814d","acronym":"IMA401-101","url":"https://clinicaltrials.gov/study/NCT05359445","created_at":"2022-05-03T14:54:12.020Z","updated_at":"2025-02-25T17:37:48.710Z","phase":"Phase 1","brief_title":"IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor","source_id_and_acronym":"NCT05359445 - IMA401-101","lead_sponsor":"Immatics Biotechnologies GmbH","biomarkers":" MAGEA4","pipe":" | ","alterations":" MAGEA4 expression • MAGEA4 overexpression","tags":["MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MAGEA4 expression • MAGEA4 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • IMA401"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 05/19/2022","start_date":" 05/19/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-01-28"},{"id":"269bcf7a-a222-4eb1-a733-a5c181aede05","acronym":"SURPASS-3","url":"https://clinicaltrials.gov/study/NCT05601752","created_at":"2022-11-05T15:14:24.529Z","updated_at":"2024-07-02T16:34:25.911Z","phase":"Phase 2","brief_title":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","source_id_and_acronym":"NCT05601752 - SURPASS-3","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • BRCA • PARP1 • MAGEA4","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • BRCA • PARP1 • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 08/12/2026","primary_completion_date":" 08/12/2026","study_txt":" Completion: 08/12/2026","study_completion_date":" 08/12/2026","last_update_posted":"2024-06-14"},{"id":"81497553-3d5a-49ef-8513-cf9cb5b29947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05642455","created_at":"2022-12-08T14:57:33.766Z","updated_at":"2024-07-02T16:35:07.743Z","phase":"Phase 1/2","brief_title":"SPEARHEAD-3 Pediatric Study","source_id_and_acronym":"NCT05642455","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 07/30/2038","study_completion_date":" 07/30/2038","last_update_posted":"2024-04-24"},{"id":"2c13cc26-0e5f-458f-80db-772216b113f8","acronym":"SPEARHEAD-1","url":"https://clinicaltrials.gov/study/NCT04044768","created_at":"2021-01-18T19:50:39.967Z","updated_at":"2024-07-02T16:35:18.934Z","phase":"Phase 2","brief_title":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT04044768 - SPEARHEAD-1","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 10/10/2021","primary_completion_date":" 10/10/2021","study_txt":" Completion: 04/01/2038","study_completion_date":" 04/01/2038","last_update_posted":"2024-02-19"},{"id":"fc2b490f-716a-4fb8-8ba2-7e656cf95939","acronym":"SURPASS","url":"https://clinicaltrials.gov/study/NCT04044859","created_at":"2021-01-18T19:50:41.997Z","updated_at":"2024-07-02T16:35:19.014Z","phase":"Phase 1","brief_title":"ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)","source_id_and_acronym":"NCT04044859 - SURPASS","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecelra (afamitresgene autoleucel) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/20/2019","start_date":" 08/20/2019","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 04/30/2037","study_completion_date":" 04/30/2037","last_update_posted":"2024-02-16"},{"id":"e1041808-e70d-49d7-83f7-a1e19c798274","acronym":" SPEARHEAD-2","url":"https://clinicaltrials.gov/study/NCT04408898","created_at":"2021-01-18T21:15:39.069Z","updated_at":"2024-07-02T16:36:20.662Z","phase":"Phase 2","brief_title":"SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer","source_id_and_acronym":"NCT04408898 -  SPEARHEAD-2","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tecelra (afamitresgene autoleucel)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-11-16"},{"id":"65ccaf9d-1aaa-48e3-98b4-14d4e6be1110","acronym":"","url":"https://clinicaltrials.gov/study/NCT02096614","created_at":"2021-01-18T09:40:44.722Z","updated_at":"2024-07-02T16:36:28.955Z","phase":"Phase 1","brief_title":"Investigator Initiated Phase 1 Study of TBI-1201","source_id_and_acronym":"NCT02096614","lead_sponsor":"Mie University","biomarkers":" MAGEA4","pipe":" | ","alterations":" MAGEA4 expression • HLA-A*24","tags":["MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MAGEA4 expression • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TBI 1201 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2021-06-18"}]